Targeting CV Outcomes with GLP-1 Receptor Agonists: What's New for Primary Care Physicians
The majority of people with type 2 diabetes will die from cardiovascular disease.It is important for all clinicians to think beyond glycemic control and review strategies to reduce cardiovascular risk in their patients with type 2 diabetes. Recent trials with GLP-1 receptor agonists have shown a potential role of these agents to not only improve glycemic control, but also to reduce the risk of a major adverse cardiovascular events (MACE) in people with type 2 diabetes.
Dr. Ron Goldenberg and Dr. John Mancini share their expert insight on the impact of cardiovascular disease in people with diabetes as well as the latest research to reduce the risk.This short and practical podcast is designed to provide primary care clinicians with a quick summary of the latest research, so that they can ensure that their patients with diabetes have the lowest possible cardiovascular risk.
John Mancini MD, FRCPC, FACC
Ronald Goldenberg MD, FRCPC, FACE